Media OutReach
Bora Navigates A Transitional 1Q26 And Sets A Strong Foundation For Rest Of The Year
Transformational Acquisitions Expected to Contribute to Long Term Growth Starting 2Q26
HONG KONG SAR – Media OutReach Newswire – 13 May 2026 – Bora Pharmaceuticals (“Bora”; TWSE: 6472; OTCQX: BORAY) today announced its financial results and operational highlights for 1Q2026 and provides full year outlook.
1Q26 Business and Financial Highlights
- The Company reported 1Q26 revenues of NT$4,001 million, down 17.68% sequentially, with basic EPS of NT$0.21. Gross margin stabilized quarter-over-quarter. The quarter reflected temporary slowdown across both businesses: pricing and demand variability in the generics market through January and February left Upsher-Smith’s 1Q26 revenue 18.63% below the trailing four-quarter run rate, while the scheduled annual maintenance of 6 weeks of our Maryland fill-finish facility limited fixed-cost absorption during the quarter, weighed on earnings quality.
- March saw a rebound in both businesses as conditions improved for both the top and bottom lines with steady demand. During the quarter, the Company advanced Maple Grove site ramp-up significantly, with several multi-year CDMO agreements signed or progressing across pharma clients of various sizes. Additionally, the Company continues to win new CDMO business as 12-month rolling backlog arrived at US$315 million. With a healthy order book at North American sites entering the second quarter, we expect fixed-cost leverage to resume, driving profit improvement as utilization builds across the installed asset base. Meanwhile, Upsher-Smith has successfully defended market share and is deploying lifecycle management initiatives that reinforce our ability to set the cadence of sales in a dynamic competitive environment.
- Non-operating loss primarily reflected a wider equity loss from affiliate Tanvex Biopharma, together with higher tax expense driven by annual 1Q recognition of tax from undistributed earnings of the previous year.
- Disciplined OPEX control has driven expenses down 14.87% quarter-over-quarter and 14.41% year-over-year. This signals that resources have settled in as we begin to see advantages in scale; The Company expects ROA and ROIC to trend gradually upward, albeit with some quarter-to-quarter variability as operating leverage builds.
- Board of Directors approved the acquisition of the CDMO business of MacroGenics Inc. (NASDAQ: MGNX), for total consideration of US$122.5 million, leading to a total 12-month rolling backlog upon closing to approximately US$375 million.
- Sunway Biotech’s Board approved the 100% acquisition of Weider Global Nutrition (“WGN”), an iconic Phoenix-based American sports nutrition brand with a strategic Costco U.S. supplier relationship, commercial presence in 60+ countries, and established positions on Amazon and Walmart. The transaction completes Bora Group’s three-platform architecture, namely CDMO, pharma sales, and nutraceuticals operated under our “dual engine” strategy.
- Share capital increased 0.04% during the quarter from employee stock option exercise.
Mr. Bobby Sheng, Chairman of Bora Group, stated, “The beginning of 2026 was eventful and challenging both in the world and at Bora. We have seen supply chain disruptions, inflation from wars, and continuous geopolitical tensions. Yet through it all, Bora Group’s disciplined approach to growth-oriented investment remained unwavering.
Our CDMO business CAPEX-to-revenue ratio reached an all-time high of over 10% in 2025, marking another year of upward progression and bringing the Company to a level comparable with established global CDMO peers. This marked a deliberate shift in where we direct investments from capacity-led expansion that defined our earlier growth chapters to a sharper focus on capability demands and modality, anchored in innovation and technology. Over the past 18 months, we have pursued an ambitious growth trajectory against a dynamic macroeconomic backdrop – recalibrating expectations, sharpening our strategy, and reaffirming long-term plans. The underlying demand environment supports our conviction: global pharma is growing at 5-8% per year, biologics CDMO outsourcing demand at 15%+ and small-molecule outsourcing demand at 8-10%. With our investment foundation now in place, we believe our CDMO business is positioned to compound organically at 13-23% annually.
In the first quarter, we executed a series of organizational adjustments, each aligned to a specific dimension of customer demand. We established the MSAT (Manufacturing, Science and Technology) function within the CDMO business, the R&D backbone of the platform, to deepen scientific and technical capability across our entire client base, an increasingly critical asset as small and mid-sized biotech and pharma clients rethink their supply chain. In parallel, we repurposed the Strategic Enterprise Account Management team into a networked model to serve clients for whom customer proximity is paramount. Together, these capability investments target specific customer pain points and position Bora to navigate the evolving political and economic landscape and capture a new chapter of commercial momentum.
To sum up, CDMO business in 1Q26 delivered US$27.2 million in total external wins on top of orders on hand, 60% or 7 molecules from pre-commercial programs. For context, full-year 2025 saw 16 pre-commercial molecule signings; 1Q26 alone has already secured nearly half that count in a single quarter. This run-rate acceleration is a leading indicator: as our capability investments take hold, forward visibility and growth potential are set to compound. Bora’s CDMO business has entered a new phase. Reinforcing this trajectory, the Group’s recently announced acquisition of MacroGenics’ Rockville, Maryland CDMO facility adds a substantial commercial-stage monoclonal antibody programs backlog and manufacturing expertise to the Group. Equipped with five 2,000-liter and two 500-liter single-use bioreactors and integrated QC and analytical labs and currently generating more than half of revenues from commercial manufacturing, the transaction marks a pivotal step in scaling Bora’s integrated biologics CDMO platform, known as Bora Biologics. DS and DP capabilities shall be integrated over the next 12–18 months to offer global biotech customers a single partner from development through commercial supply in the U.S..
On the pharma sales side, the Group faced competition across a handful of core generic products. Upsher-Smith is navigating the competitive landscape with a clear focus on the most margin-accretive opportunities while continuing to scout niche, brand-oriented assets. Near-term, DLS market share has been defended; over the medium term, sustained market share maximization of the infantile spasm franchise coupled with swift pipeline replenishment weighted toward differentiated assets is critical. In the first quarter, we saw unique patients for VIGAFYDE grew by more than 140% over same period last year and a continuous increase in new patients. Both healthy signs of steady execution pace building up to durable resilience in the pharma sales business.”
1Q26 Operational Achievements & 2026 Outlook
Global CDMO Operations
Revenues declined 24.62% year-over-year and 30.15% quarter-over-quarter including internal orders, mainly due to above-mentioned maintenance at fill and finish facility in Maryland, a routine cycle factored into our operating plan, and seasonality at Canada site. To scale biologics CDMO one-stop-shop platform in commercialized projects with SUB (Single Use Bioreactors) in the US; Board of Directors approved the acquisition of Rockville, Maryland based drug substance facility from MacroGenics for US$122.5 million.
Following closing, Bora Group intends to leverage the Rockville Site in cooperation with Tanvex Biopharma (TWSE: 6541), which operates the Group’s biologics CDMO franchise under the “Bora Biologics” brand. Together with Bora’s sterile drug product capabilities, this is expected to expand and strengthen the Group’s end-to-end biologics platform. The Rockville facility has operated as an outsource manufacturing partner since 2022 and is equipped with five 2,000-liter and two 500-liter single-use bioreactors and fully integrated QC and analytical laboratories and has been inspected by both the U.S. FDA and Japan’s PMDA.
During the quarter, 0.44 billion doses, or 108 molecules, were developed and manufactured. Excluding internal orders, the business accounted for 37.73% of consolidated revenues. Contribution from the top 20 global pharmaceutical companies stood at 32.10%.
As the Company continues to expand its CDMO capacity and capabilities, this year’s CAPEX plan is closely linked to the contracting cadence of a key customer anchored at Bora’s North American CDMO network. The Group expects to complete Maple Grove’s capital expenditure program in the first half of the year, sequencing the investment to grow in step with major pharmaceutical partners’ supply chain plans and optimize return on capital deployed.
Pharma Sales Operations
Discontinued operations impact in 2025 has materially abated this quarter, positioning Upsher-Smith to re-accelerate organic growth in 2026. Management has defined two strategic priorities for 2026, designed to enhance capital efficiency and sharpen commercial focus:
First, R&D capital allocation optimization. 505(b)(2) Pipeline programs have been transferred to Salus Therapeutics, an equity-method affiliate. Under this structure, Upsher-Smith retains the right to economic participation in commercial outcomes while shareholders’ exposure to early-stage development and regulatory risks, and associated cash burden is meaningfully reduced. The decision is consistent with the Group’s capital discipline observed across businesses.
Second, institutionalizing pipeline expansion capabilities. An integrated business development and medical affairs function is being established to systematically evaluate in-licensing, co-promotion, and bolt-on opportunities. This integrates Bora’s proven asset-selection and M&A strategy directly into Upsher-Smith’s commercial infrastructure, enabling franchise compounding through targeted external sourcing rather than capital-intensive internal development. These lifecycle initiatives focus but are not limited to pediatric epilepsy opportunities.
Collectively, Management expects Upsher-Smith to evolve fully into a capital efficient, commercially led, and therapeutically centered vehicle designed to deliver sustained shareholder value before exiting 2026.
Recent Investor Conference
Bora will host English online earnings call at 7:30 a.m. Taiwan time on May. 14th, 2026. The event will cover the Company’s 1Q26 financial and business results and 2026 outlook.
English Online Earnings Presentation Link: https://events.q4inc.com/attendee/372103448
Bora will participate in 2026 Yuanta Securities Investment Forum in June. For 1:1 meetings with management, please contact your Yuanta representative.
Bora 2026 Earnings Schedule
Q2 2026: Expected in the 2nd week of Aug 2026
Q3 2026: Expected in the 2nd week of Nov 2026
Q4 2026: Expected in the 2nd week of Mar 2027
Hashtag: #BoraPharmaceuticals
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.
For more, please visit:
https://www.bora-corp.com
https://www.boracdmo.com
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
Three new Laguna Phuket developments – spanning lakeside living, golf-front design and Angsana-branded luxury – to be showcased at Fairmont Singapore on 23–24 May
SINGAPORE – Media OutReach Newswire – 14 May 2026 – Banyan Group Residences is bringing three of its most anticipated new residential launches to Singapore this month, with a two-day sales exhibition taking place at Fairmont Singapore, Orchard Room (4F) on Saturday 23 and Sunday 24 May 2026, from 11:00 am to 6:00 pm. The event offers Singapore buyers a rare opportunity to explore and invest in some of Phuket’s most compelling new addresses, with dedicated sales teams on hand for private consultations.
The exhibitions follow a year of record residential sales for Banyan Group Residences, as growing numbers of global investors look to Phuket as a safe haven for capital – drawn by the island’s political stability, strong rental yields, year-round lifestyle appeal, and the relative value it continues to offer against comparable markets. Demand has been particularly robust from buyers across Asia, the Middle East, and Europe, with Singapore consistently ranking among the Group’s top source markets worldwide.
The three projects on show represent some of the most exciting new additions to Laguna Phuket – Asia’s premier integrated resort destination – and span a range of living concepts, price points, and design inspirations, united by the hallmark quality and hospitality expertise of Banyan Group Residences, Asia’s leading branded residential developer by volume.
“Singapore has long been one of our most important buyer markets, and we’re delighted to be returning with what we believe is our strongest line-up yet,” said Stuart Reading, Managing Director of Banyan Group Residences. “Whether you’re looking for a holiday retreat, a permanent base in a world-class resort community, or a smart long-term investment, this exhibition offers something genuinely compelling. High-quality property in a prime location at Laguna Phuket still represents outstanding value compared to equivalent homes in Singapore or other major cities.”
Bellaguna Lake Residences
Brand new blocks of Bellaguna Lake Residences will be revealed for the first time at the exhibition. Set beside a shimmering lake within Laguna Phuket – steps from Bang Tao Beach – the development takes its design cues from the sleek lines of a contemporary luxury yacht. Five elegantly elongated buildings feature dark wave-like façades and warm, light-filled interiors, with generous private terraces overlooking the lagoon. Residences include one- to three-bedroom condominiums and two- to three-bedroom penthouses with private rooftop pools, as well as a brand new category of two-bedroom residences with private pool.
Bellaguna is Banyan Group Residences’ newest residential brand, conceived specifically for premium year-round living outside of hotel inventory – yet fully supported by the Group’s renowned hospitality management standards.
Bellaguna Golf Residences
Set on land that once formed part of Phuket’s historic tin-mining landscape, Bellaguna Golf Residences draws its design identity from that heritage – soft horizontal lines and sculpted contours reinterpreted through a contemporary tropical lens. Low-rise buildings unfold amid lush gardens and a signature free-form pool, overlooking the fairways of the championship Laguna Golf Phuket course. A brand new block has also just been released for this project, which features a compact one-bedroom configuration, alongside one- to three-bedroom condominiums and two- to three-bedroom penthouses with private pools and sunset golf views.
Angsana Golf Residences Topaz
Inspired by the clarity and elegance of the topaz gemstone, Angsana Golf Residences Topaz comprises three gracefully curved low-rise buildings set within Laguna Phuket, with Sino-Portuguese design accents that subtly reference Phuket’s cultural heritage. The development offers two- and three-bedroom residences and exclusive penthouses with private rooftop pools, all enjoying panoramic views of the golf course, mountains, and the Andaman Sea. A signature rooftop ring-shaped pool completes the picture.
Show units are now available for all three projects at the Laguna Property Sales Gallery.
Banyan Living
Banyan Group has recently launched Banyan Living, a residential rental and marketing platform created to support owners of branded residences across the Group’s portfolio, while offering guests a professionally managed alternative to traditional home‑sharing platforms.
Developed as a structured, hospitality-led rental ecosystem, Banyan Living enables private owners to generate income from their residences, while providing guests who rent the properties assurance of the design integrity and professional service standards associated with Banyan Group.
Why Phuket, Why Now
Phuket continues to attract growing international interest as both a lifestyle destination and an investment market. Within Laguna Phuket, nationals of some 70 countries have chosen to make the resort community their home, drawn by year-round tropical living, world-class amenities, international schools, medical facilities, and a level of quality and security that is difficult to match elsewhere in the region.
Banyan Group Residences anticipates launching up to USD 1 billion in new luxury residential projects in Phuket over the next two to three years, reflecting the Group’s confidence in the market and the enduring strength of demand from international buyers.
Prospective buyers are welcome to visit the exhibition at Fairmont Singapore, Orchard Room (4F), on Saturday 23 and Sunday 24 May 2026, between 11:00 am and 6:00 pm. Private appointments can be arranged in advance by contacting the team directly.
Hashtag: #BanyanGroup #BanyanGroupResidences #LagunaPhuket
The issuer is solely responsible for the content of this announcement.
About Banyan Group
Banyan Group (“Banyan Tree Holdings Limited” or the “Group” – SGX: B58) is an independent, global hospitality company with purpose. The Group prides itself on its pioneering spirit, design-led experiences and commitment to responsible stewardship. Its extensive portfolio spans more than 100 properties, over 140 spas and galleries, and 20-plus branded residences in over 20 countries. Comprising 12 global brands, including the flagship Banyan Tree, each distinct yet united under the experiential membership programme with Banyan. The founding ethos of “Embracing the Environment, Empowering People” is embodied through the Banyan Global Foundation and Banyan Management Academy. Banyan Group is committed to remaining the leading advocate of sustainable travel, with a focus on regenerative tourism and innovative programmes that elevate the guest experience.
About Laguna Phuket
Laguna Phuket is Asia’s premier integrated resort destination, set against the stunning backdrop of the Andaman Sea. Spanning over 1,000 acres, the resort features six luxury hotels, an award-winning 18-hole golf course, fine dining, luxury spas, and branded residences. Guests benefit from complimentary shuttle services, a cashless payment system, and access to world-class recreational and wellness facilities.
About Banyan Group Residences
Banyan Group Residences is the property development arm of leading hospitality pioneer Banyan Group, listed on the stock exchange of Singapore. With over 35 years of development experience and an impressive portfolio of residential brands to suit different lifestyles and budgets, it is Thailand’s leading lifestyle property developer with a strong and increasingly international pipeline of projects. The Group’s main residential brands include the flagship luxury Banyan Tree Residences, Angsana Residences, Dhawa Residences, Garrya Residences, Laguna Residences, Cassia Residences, Skypark, Laguna Lakelands, and Bellaguna.
Media OutReach
CPF NH Foods Advances to Production Phase, Launches ‘CP Nippon’ Brand in Premium Processed Pork Partnership
The start of operations follows the successful establishment of the joint venture in late 2025, combining CPF’s fully integrated supply chain and regional distribution network with NH Foods’ advanced food processing technologies and product development expertise. The facility now serves as the production hub for a new generation of high-quality processed meat products, targeting both domestic and export markets including Japan, Hong Kong, Singapore, and other key Asian destinations.
Prasit Boondoungprasert, Chief Executive Officer of CPF, said “Starting production and introducing CP Nippon brand mark an important milestone in our partnership with NH Foods. This collaboration enables us to move beyond primary production to premium processed products, creating greater value for Thailand’s pork industry while strengthening its position as a key exporter across Asia.”
The manufacturing facility integrates advanced production systems and stringent quality assurance processes aligned with international standards, reinforcing both companies’ commitment to food safety, traceability, and sustainability. By leveraging CPF’s high-quality raw material sourcing and NH Foods’ precision manufacturing know-how, the joint venture aims to set new benchmarks in processed meat production.
Fumio Maeda, President and Chief Executive Officer of NH Foods, added “The commencement of production represents a key milestone in our collaboration with CPF. By combining our strengths in technology and product innovation with CPF’s operational excellence, we are bringing together the rich culinary traditions of Japan and Thailand to deliver refined, high-quality food experiences to consumers across Asia.”
The product range under CP Nippon brand reflects NH Foods’ Japanese culinary expertise—rooted in the craftsmanship of ryōrinin—combined with CPF’s strength in high-quality sourcing and production.
Beyond product innovation, CPF NH Foods is committed to sustainable manufacturing practices, including efficient resource utilization and environmentally responsible operations, in line with CPF’s “Kitchen of the World” vision and both companies’ long-term sustainability goals.
Hashtag: #AsianFoodInnovation #CPFNHFoods #CPFNippon #KitchenOfTheWorld #FoodInnovation #CPF
https://www.cpfworldwide.com/en/home
The issuer is solely responsible for the content of this announcement.
About Charoen Pokphand Foods Plc (CPF)
Charoen Pokphand Foods Plc (CPF) is a leading global agro-industrial and food company, operating in 17 countries and exporting to more than 50 markets worldwide. Guided by its “Kitchen of the World” vision, CPF focuses on delivering safe, high-quality, and nutritious food through a vertically integrated business model. The company integrates technology and innovation across its operations while advancing sustainability and working toward a low-carbon, resilient food system that supports global food security.
About NH Foods
NH Foods Ltd., operates in the food industry with a focus on meat products and related processed foods. The group conducts its business globally, and targets both domestic and international markets for its diversified protein and food solutions portfolio.
Media OutReach
Student Life and Campus Communities Are Becoming a Key Deciding Factor in Higher Education
This shift reflects a broader trend across the sector, where institutions are being evaluated not only on academic outcomes, but also on their ability to provide holistic student experiences that support mental wellbeing, social integration, and career readiness.
At the Singapore Institute of Management (SIM), student engagement has become a central pillar of the learning experience, with a wide network of student led clubs and communities designed to support both personal and professional development.
A Growing Priority: Belonging and Wellbeing
Industry observations indicate that students, particularly those transitioning from secondary education or arriving from overseas, often face challenges such as social isolation, cultural adjustment, and limited peer support networks. Research also highlights that being away from familiar support systems and adapting to a new cultural and academic environment can be an isolating process, contributing to increased stress, anxiety, and reduced perceived social support
To address this, SIM has developed a structured student life ecosystem supported by its Student Development initiatives and programmes such as Project1095, which emphasises learning beyond the classroom and holistic growth. With close to 80 student clubs and co-curricular activities available, students are provided with multiple avenues to build connections and integrate into campus life.
From Co-Curricular Activities to Career Readiness
Student clubs are increasingly seen as more than recreational clubs, playing a meaningful role in preparing students for the workforce. Participation in such communities enables students to develop transferable skills aligned with employer expectations, including leadership, collaboration, and communication.
At SIM, student led initiatives span a broad spectrum, from arts and cultural groups that foster creativity and teamwork through performances and events, to sports and wellness communities that promote physical resilience and discipline. Leadership platforms such as student councils provide opportunities for students to organise initiatives and represent the student body, while international student communities support cultural integration and inclusivity.
In addition, special interest and professional clubs offer exposure to industry trends and peer led learning. Collectively, these platforms provide practical experiences that complement academic programmes and contribute to graduates’ overall employability.
Reflecting a Broader Shift in Higher Education
The increasing importance placed on student life reflects a wider evolution in higher education, where institutions are expected to support both academic achievement and personal development.
By investing in student communities and engagement, institutions like SIM are responding to this shift, providing environments where students can not only gain qualifications, but also build networks, resilience, and a strong sense of identity.
As prospective students weigh their options, the availability of vibrant campus communities and support systems is likely to remain a key differentiator in the higher education landscape.
Reference:
- The experience of loneliness among international students participating in the BBC Loneliness Experiment: Thematic analysis of qualitative survey data – https://www.sciencedirect.com/science/article/pii/S2666518223000189?
- Mental health concerns and needs of international students in higher education settings: A scoping review protocol – https://pmc.ncbi.nlm.nih.gov/articles/PMC12334020/
- SIM CCA – https://www.sim.edu.sg/degrees-diplomas/life-at-sim/co-curricular-activities
- SIM Project 1095 – https://project1095.simge.edu.sg/
Hashtag: #SIMGlobalEducation #SIMGE #GlobalEducation #InternationalDegree #CareerReady #FutureSkills
The issuer is solely responsible for the content of this announcement.
About SIM Global Education
SIM Global Education (SIM GE) is a leading private education institution in Singapore and the region. We offer more than 140 academic programmes ranging from diplomas and graduate diploma programmes to bachelor’s and master’s degree programmes with some of the world’s most reputable universities from Australia, Canada, Europe, United Kingdom, and the United States. SIM GE’s cohort is made up of 17,000 full- and part-time students and adult learners, of which approximately 41% are international students hailing from over 50 countries.
SIM GE’s holistic learning approach and culturally diverse learning environment aim to equip students with knowledge, industry skills and employability competencies, as well as a global perspective to succeed as future leaders in a fast-changing, technologically driven world.
For more information on SIM Global Education, visit www.sim.edu.sg
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn